- Home
- ZEO vs ACXP Comparison
ZEO vs ACXP Comparison
Compare ZEO & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEO
- ACXP
- Stock Information
- Founded
- ZEO 2005
- ACXP 2017
- Country
- ZEO United States
- ACXP United States
- Employees
- ZEO N/A
- ACXP N/A
- Industry
- ZEO
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- ZEO
- ACXP Health Care
- Exchange
- ZEO NYSE
- ACXP Nasdaq
- Market Cap
- ZEO 55.5M
- ACXP 8.4M
- IPO Year
- ZEO N/A
- ACXP 2021
- Fundamental
- Price
- ZEO $3.02
- ACXP $0.53
- Analyst Decision
- ZEO
- ACXP Strong Buy
- Analyst Count
- ZEO 0
- ACXP 2
- Target Price
- ZEO N/A
- ACXP $10.00
- AVG Volume (30 Days)
- ZEO 170.4K
- ACXP 18.5M
- Earning Date
- ZEO 06-16-2025
- ACXP 08-08-2025
- Dividend Yield
- ZEO N/A
- ACXP N/A
- EPS Growth
- ZEO N/A
- ACXP N/A
- EPS
- ZEO N/A
- ACXP N/A
- Revenue
- ZEO $61,885,622.00
- ACXP N/A
- Revenue This Year
- ZEO N/A
- ACXP N/A
- Revenue Next Year
- ZEO N/A
- ACXP N/A
- P/E Ratio
- ZEO N/A
- ACXP N/A
- Revenue Growth
- ZEO N/A
- ACXP N/A
- 52 Week Low
- ZEO $1.05
- ACXP $0.30
- 52 Week High
- ZEO $4.75
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- ZEO 55.75
- ACXP 47.99
- Support Level
- ZEO $2.77
- ACXP $0.52
- Resistance Level
- ZEO $3.25
- ACXP $0.63
- Average True Range (ATR)
- ZEO 0.44
- ACXP 0.09
- MACD
- ZEO -0.06
- ACXP 0.00
- Stochastic Oscillator
- ZEO 52.86
- ACXP 17.33
About ZEO ZEO ENERGY CORP
Zeo Energy Corp is a vertically integrated provider of residential solar energy systems, other energy-efficient equipment, and related services currently serving customers in Florida, Texas, Arkansas, and Missouri. Its primary business activity is selling and installing residential solar energy systems that homeowners use to supplement the amount of usable electricity required to power their homes.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.